Pfizer (NYSE:PFE | PFE Price Prediction) is in the middle of its biggest reinvention in a generation, leaning on the Seagen oncology platform and the freshly closed Metsera obesity assets to offset a COVID revenue cliff and looming patent losses. With shares at $25.60 and yielding nearly 7%, the only question that matters for income investors is whether that payout is actually safe.
Dividend Snapshot
| Metric | Value |
|---|---|
| Annual Dividend | $1.72 |
| Dividend Yield | 6.70% |
| Consecutive Years of Increases | ~16 years |
| Most Recent Increase | 2.4% (late 2025) |
| Aristocrat/King Status | No (cut in 2009) |
FCF Coverage Is Tighter Than the Earnings Payout Suggests
On adjusted EPS of $3.22, the $1.72 dividend works out to roughly a 53% earnings payout. The cash math is less generous. Pfizer generated $11.7 billion in operating cash flow in 2025 against $2.6 billion in capex, leaving $9.08 billion in free cash flow versus $9.77 billion paid in dividends.
| Metric | TTM | Assessment |
|---|---|---|
| Earnings Payout Ratio | ~53% | Healthy |
| FCF Payout Ratio | ~108% | Concerning |
| OCF / Dividend | 1.20x | Adequate |
FCF coverage slipped from 1.03x in 2024 to 0.93x in 2025. The check is clearing, but the buffer is thin.
Leverage From the Seagen Deal Still Casts a Shadow
| Metric | Value | Assessment |
|---|---|---|
| Debt-to-Equity | 0.78 | Moderate |
| Net Debt/EBITDA | 3.26x | Elevated |
| Interest Coverage | 5.78x | Adequate |
Pfizer ended Q1 at 2.8x leverage by management’s measure, and deleveraging is explicitly tied to dividend protection.
Sixteen Straight Raises, but the 2009 Cut Still Counts
| Year | Annual Dividend |
|---|---|
| 2026 | $1.72 |
| 2024 | $1.68 |
| 2022 | $1.60 |
| 2020 | $1.52 |
Pfizer halved the dividend in 2009 to fund the Wyeth deal, so this is not a Dividend Aristocrat. Growth has also cooled to a roughly 2.4% bump for 2026.
Management Calls the Dividend a Priority
CEO Albert Bourla told investors on the Q1 2026 call: “We also remain deeply committed to our shareholders. We intend to maintain and, over time, grow our dividend as we continue to delever and build long-term value.” CFO David Denton placed the dividend ahead of buybacks, and no repurchases are planned for 2026 despite $3.3 billion in remaining authorization.
Verdict: Safe for Now, but Watch the Cash Flow
Dividend Safety Rating: Moderate Risk. The earnings payout is fine, management is vocal, and Q1 2026 revenue grew 5.4% with launched and acquired products up 22% operationally. An FCF payout above 100% and elevated leverage complicate the safe-haven label. The dividend thesis strengthens if oncology and the Metsera obesity ramp push free cash flow back above $10 billion. The risk profile worsens if 2027 FCF coverage stays under 1.0x while Eliquis erosion accelerates.
Top Gaining Stocks
Top Losing Stocks